MXC: $0.023

Doctors are very important to MGC Pharmaceuticals, because they are the gateway to our patients.

Our Doctors have the most influence on the integration of Phytocannabinoid therapy into our world’s existing scope of treatments. That’s why MGC Pharma strives to educate doctors about Medical Cannabis and the Endo-Cannabinoid system, in order to facilitate new and innovative solutions for patients that offer relief from many of today’s prevalent diseases.

Doctors' Access

In MGC Pharma’s Doctor access point, doctors can discover information about Medical Cannabis and engage with MGC in order to gain approval to prescribe in Australia. They can also familiarise themselves with MGC’s R&D and clinical pipelines in order to understand the changes that will be coming with the inclusion of Phytocannabinoid medications within the existing treatment spectrum.

Currently in Australia, there are three pathways to prescribe MGC products:

Doctors in Australia wishing to contact MGC Pharma, or find out more about Australia’s prescription process, please contact

Sign up to receive information on how to prescribe Medicinal Cannabis in Australia, Science, Regulation and the industry as a whole.


An introduction to the Endocannabinoid System – Pharmaceutical Society of Australia February 2018. Presented by Justin Sinclair Research Fellow, NCIM (Western Sydney University)

Medical Cannabis for Australian Pharmacists PSA Webinar. Presented by Paul Mavor B.Pharm

Cannabidiol (CBD) in Refractory Epilepsy. Presented by Professor Uri Kramer